Hello, I meant to post an introduction but am having difficulty (my problem). I have a question please -
Does anyone know if there is any updated information about outcomes from the BILCAP trial? Or is there any other information suggesting whether Gemcitabine or Capecitabine is more likely to be effective as adjuvant therapy?
My husband is due to start chemotherapy in a couple of weeks' time after his second resection (last month) for intrahepatic CC. He has clean margins again and is doing well - back at work part-time and riding his bike. His tumour was said to be ductular on the path report the first time and while there have been several recent papers regarding possible differences between intrahepatic CC arising from ductules vs ducts, I don't think there is much about what that might mean for therapy. Like many who get this disease, he had no obvious risk factors. He didn't have chemo after the first resection (October '11). The second tumour was probably there after the first operation but too small to be seen on the post-op scan.
We thought he would be offered Gemcitabine this time but the oncologist has given us the choice of Gemcitabine or Capecitabine. We've said Gemcitabine but thought I'd ask if anyone knows more.
Thanks to the moderators and everyone involved with this board.